New Diabetic Research
At ADA, JDRF-Funded Research Takes Center Stage
At the American Diabetes Association’s Scientific Sessions, which was held virtually from June 25-29, scientists presented on some of the most important topics, from beta cell replacement trials to screening to low blood sugar treatments, all with the same goal: Ending type 1 diabetes (T1D).
Finding T1D IN A Person Before Experiencing Health Issues
General Population Screening Reduces Life Threatening Diabetic Ketoacidosis, New Research Shows
NEW YORK– January 28, 2020 —JDRF, the leading global organization funding type 1 diabetes (T1D) research, today announced new research that found widespread screening for islet autoantibodies reduced the occurrence of life-threatening diabetic ketoacidosis (DKA) among children with pre-symptomatic T1D.
Steps Towards Preventing Diabetes
It’s Official: Teplizumab is Under Review by the FDA
The U.S. Food and Drug Administration (FDA) regulatory review is now under way for teplizumab—a therapy that blocks the blood marker CD3, which activates immune cells—to prevent or delay type 1 diabetes (T1D) in at-risk individuals. The target action date is July 2, 2021.
New Diabetic Technologies
Tandem Control-IQ Controls T1D in Children Ages 6 and Up
A clinical trial at four pediatric diabetes centers in the United States has found that a new artificial pancreas system—which automatically monitors and regulates blood-sugar levels—is safe and effective in children as young as age six with type 1 diabetes (T1D)
SFC Fluidics, a JDRF Partner, Receives Breakthrough Device Designation
SFC Fluidics Insulin Patch Pump Last month, SFC Fluidics received a breakthrough device designation for the company’s interoperable insulin delivery pod from the Food and Drug Administration (FDA).
99 years closer: About our FDA submission of Tidepool Loop
As a dad of a child with type 1 diabetes, I can’t help but note the significance of today’s date. On January 11, 1922—99 years ago—a 14-year-old boy with diabetes named Leonard Thompson received the very first injection of insulin.
Improving Diabetic Complications and Behavioral Health
FDA Approves Lucentis to Treat Diabetic Macular Edema
For many people who have experienced diabetic macular edema (DME), the future looks a little clearer. On August 10, 2012, the U.S. Food and Drug Administration (FDA) approved use of the drug Lucentis for the treatment of DME. Developed by Genentech, Lucentis is the first and only FDA-approved medicine for the condition.
Educators Align at the American Association of Diabetes Educators (AADE) Conference
Each year, diabetes educators from all over the world—including Nicole Johnson, DrPH, MPH, National Director, JDRF Mission—gather for the annual meeting of the American Association of Diabetes Educators (AADE), which took place August 9-12 in Houston, Texas. The AADE’s aim is to drive optimal outcomes through integration of diabetes clinical management, self-management education, prevention and support.